Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Metastasis and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DAND5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DAND5 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native disulfide-bonded knot conformation. |
View DAND5 Products |
| Gene Delivery | DAND5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling assays. |
View DAND5 Products |
| Benchmark Ab | Anti-DAND5 Recombinant Antibody Recombinant positive control derived from public therapeutic sequences. Sequence verified. |
View DAND5 Products |
| Validator | DAND5 siRNA Set Target-specific pool for gene knockdown and functional specificity validation. |
View DAND5 Products |
| Related Target A | BMP4 Primary ligand antagonized by DAND5; critical for establishing target-engagement and rescue assays. |
View BMP4 Products |
| Related Target B | GREM1 Homologous DAN family member; essential for counter-screening to ensure antibody selectivity. |
View GREM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Cysteine Knot | HEK293 mammalian expression system ensures correct folding and native glycosylation patterns of the DAND5 cysteine knot structure. |
| Subfamily Cross-Reactivity (Gremlin/Cerberus) | High-purity homolog panel (GREM1, SOSTDC1) available for rigorous selectivity and off-target screening. |
| Lack of Validated Control Reagents | Sequence-verified clinical benchmark antibodies and positive control expression plasmids included in the catalog. |
| Assay Artifacts and False Positives | Sequence-verified siRNA pools included for target knock-down validation in functional cell-based assays. |
Live DAND5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of DAND5 (also known as COCO) is an emerging frontier in oncology and regenerative medicine. In cancer biology, DAND5 acts as a secreted antagonist of BMP (Bone Morphogenetic Protein) signaling, crucially mediating the reactivation of dormant breast cancer metastases in the lungs, brain, and bones. Inhibiting DAND5 represents a highly promising strategy to maintain tumor dormancy and prevent metastatic outgrowth.
The race for DAND5 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted monoclonal antibodies and RNA-based therapeutics. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting the specific disruption of the DAND5-BMP interaction interface without cross-reacting with closely related DAN family proteins like Gremlin-1 or Sclerostin.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Medical Centers, Biotech Startups | Metastatic Breast Cancer, Lung Metastasis | Blocking Assay (Requires high-purity, native-conformation DAND5 ECD-Fc for SPR/ELISA) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Advanced Solid Tumors | In vitro knockdown verification (Requires sequence-verified siRNA and RT-qPCR controls) |
| Small Molecule Inhibitors | Oncology-focused Biopharma | Metastatic Reactivation Prevention | High-throughput screening (Requires stable cell line expression via Lentivirus Premade Particles) |